KRAS-mutant pancreatic cancer remains one of oncology's most formidable challenges, with fewer than 12% of patients surviving five years. Any strategy capable of dismantling the MAPK signaling cascade that KRAS mutations chronically activate would represent a meaningful leap forward — which is precisely what made the SHERPA trial's dual-inhibitor approach so eagerly anticipated.
The trial enrolled 24 patients with KRAS-mutant pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer, or colorectal cancer, pairing the SHP2 inhibitor RMC-4630 with the ERK inhibitor LY3214996 across four dose levels in 28-day cycles. Of the 19 patients evaluable for dose-limiting toxicities (DLTs), six DLTs emerged across three of four dose escalation levels — effectively preventing the combination from reaching therapeutic dose ceilings. Toxicities were heterogeneous and clinically concerning: grade 3 thrombocytopenia appeared in three patients, while a reduced left ventricular ejection fraction, acute kidney injury, and severe diarrhea accounted for the remainder. Only the lowest active dose level (100 mg RMC-4630 plus 200 mg LY3214996) cleared the DLT threshold. Pharmacodynamic data offered a partial signal of biological activity — phosphorylated S6 ribosomal protein, a downstream MAPK readout, declined significantly — yet this molecular response did not translate into measurable radiological tumor regression.
This outcome reflects a persistent pattern in vertical MAPK pathway co-inhibition: the same signaling nodes targeted in tumor cells are indispensable in healthy tissues, particularly cardiac and renal compartments. Earlier attempts combining MEK inhibitors with ERK or RAS-directed agents encountered nearly identical toxicity profiles, suggesting the therapeutic window for complete MAPK blockade may be inherently narrow. The SHERPA results underscore why intermittent dosing strategies, tumor-selective delivery, or rational biomarker-driven patient selection may be prerequisites — not refinements — for this class of combinations. As a phase I safety study, the trial was not powered for efficacy, and the small cohort limits generalizability. Still, the biologic rationale remains sound, and the phospho-S6 signal hints that optimized dosing or sequencing could yet unlock clinical benefit.